GSK Files 2025 Annual Report and Sets Timeline for AGM Materials

An announcement from GlaxoSmithKline ( (GB:GSK) ) is now available.

GSK has published its Annual Report for the year ended 31 December 2025 on its dedicated reporting website, fulfilling key UK regulatory obligations by also submitting the document to the Financial Conduct Authority’s National Storage Mechanism for public inspection. The company will distribute hard copies of the Annual Report and the 2026 AGM notice to shareholders who opt for paper communications around 25 March 2026, while making the AGM materials available to all investors on the same date, underscoring its focus on regulatory compliance and transparent information access for stakeholders.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.

The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GSK is a global biopharma company focused on uniting science, technology, and talent to develop medicines and vaccines that help prevent and treat disease worldwide. Headquartered in London and registered in England and Wales, the company operates across major healthcare markets, targeting a broad range of therapeutic areas through research-driven innovation.

Average Trading Volume: 8,996,167

Technical Sentiment Signal: Buy

Current Market Cap: £84.77B

Learn more about GSK stock on TipRanks’ Stock Analysis page.